Literature DB >> 33602892

Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance.

Sutapa Sinha1, Charla R Secreto1, Justin C Boysen1, Connie Lesnick1, Zhiquan Wang1, Wei Ding1, Timothy G Call1, Saad J Kenderian1, Sameer A Parikh1, Steven L Warner2, David J Bearss2, Asish K Ghosh3, Neil E Kay4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33602892      PMCID： PMC7893033          DOI： 10.1038/s41408-021-00426-2

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  15 in total

Review 1.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

Review 2.  Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer.

Authors:  Jiujie Cui; Weihua Jiang; Shuyi Wang; Liwei Wang; Keping Xie
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse.

Authors:  E Braggio; N E Kay; S VanWier; R C Tschumper; S Smoley; J E Eckel-Passow; T Sassoon; M Barrett; D L Van Dyke; J C Byrd; D F Jelinek; T D Shanafelt; R Fonseca
Journal:  Leukemia       Date:  2012-01-20       Impact factor: 11.528

4.  Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin.

Authors:  Yanli Jin; Danian Nie; Juan Li; Xin Du; Yuhong Lu; Yangqiu Li; Chang Liu; Jingfeng Zhou; Jingxuan Pan
Journal:  Clin Cancer Res       Date:  2016-11-16       Impact factor: 12.531

5.  RhoC maintains vascular homeostasis by regulating VEGF-induced signaling in endothelial cells.

Authors:  Luke H Hoeppner; Sutapa Sinha; Ying Wang; Resham Bhattacharya; Shamit Dutta; Xun Gong; Victoria M Bedell; Sandip Suresh; Changzoon Chun; Ramani Ramchandran; Stephen C Ekker; Debabrata Mukhopadhyay
Journal:  J Cell Sci       Date:  2015-07-01       Impact factor: 5.285

6.  Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.

Authors:  Sutapa Sinha; Justin Boysen; Michael Nelson; Charla Secreto; Steven L Warner; David J Bearss; Connie Lesnick; Tait D Shanafelt; Neil E Kay; Asish K Ghosh
Journal:  Clin Cancer Res       Date:  2015-02-11       Impact factor: 12.531

7.  Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.

Authors:  Qingqing Ding; Weiya Xia; Jaw-Ching Liu; Jer-Yen Yang; Dung-Fang Lee; Jiahong Xia; Geoffrey Bartholomeusz; Yan Li; Yong Pan; Zheng Li; Ralf C Bargou; Jun Qin; Chien-Chen Lai; Fuu-Jen Tsai; Chang-Hai Tsai; Mien-Chie Hung
Journal:  Mol Cell       Date:  2005-07-22       Impact factor: 17.970

8.  Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells.

Authors:  S Sinha; J Boysen; M Nelson; S L Warner; D Bearss; N E Kay; A K Ghosh
Journal:  Leukemia       Date:  2015-11-24       Impact factor: 11.528

Review 9.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

10.  AXL mediates resistance to cetuximab therapy.

Authors:  Toni M Brand; Mari Iida; Andrew P Stein; Kelsey L Corrigan; Cara M Braverman; Neha Luthar; Mahmoud Toulany; Parkash S Gill; Ravi Salgia; Randall J Kimple; Deric L Wheeler
Journal:  Cancer Res       Date:  2014-08-18       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.